The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases

Pach, Jolanta; Valido, Kailyn; Belzer, Annika; Leventhal, Jonathan S.

doi:10.1007/s40257-024-00866-z

Am J Clin Dermatol

2024

DOI: 10.1007/s40257-024-00866-z

|View full text |Cite

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases

Jolanta Pach,

Kailyn Valido,

Annika Belzer

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system

Tan,

Chen,

Chen

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

This study aimed to describe bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICIs) reported in the United States Food and Drug Administration adverse event reporting system (FAERS). We obtained reports of ICI‐associated BP from the first quarter of 2011 to the first quarter of 2024 in the FAERS database. The reporting odds ratio (ROR) method of the disproportionality analysis was performed to assess the potential risk for ICI‐associated BP. We also described the clinical characteristics of ICI‐associated BP and evaluated the time to onset (TTO) of BP developed after treatment with ICIs. Eight hundred and six cases of ICI‐associated BP were gathered, in which 56.58% of the patients were aged 65 years or older. The majority of patients were male, accounting for 68.49% of all cases. The prevalent potential cancer type was skin cancer (31.64%). The results of the disproportionality analysis showed that males (ROR = 2.10 [1.78–2.49]), patients aged 65 or older (ROR = 2.13 [1.79–2.55]), and patients with skin cancer (ROR = 2.08 [1.80–2.43]) were more likely to develop ICI‐associated BP. In comparison to cytotoxic T‐lymphocyte‐associated antigen 4 inhibitor and programmed cell death ligand 1 inhibitor, programmed cell death 1 inhibitor‐associated BP has a higher risk of development (ROR = 24.45 [22.52–26.56]). ICI‐associated BP had a median TTO of 204 days (interquartile range 57–426 days). ICI‐associated BP is a rare but important immune‐related adverse event. Our study provided helpful information to help medical professionals further understand ICI‐associated BP.

show abstract

Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system

Tan,

Chen,

Chen

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases

Cited by 1 publication

References 96 publications

Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system

Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system

Contact Info

Product

Resources

About